Skip to content

DOC Healthpeak Properties

S&P 500
Weak · 23/100
Real Estate
Health Care REITs

$18.86

▼ 0.5%

Updated Oct 16, 2:25 PM ET

Report Card

DOC at a glance — five pillars scored 0–100 from real filed financials.

How the 0–100 rating is calculated
Value
37
Growth
13
Profitability
18
Health
34
Dividends
100

Overall: Weak · 23/100. A wider, greener shape means more pillars look healthy. Dividends scores 0 when a company pays none — that is a choice, not a flaw.

Price — Past Year

▲ Up 14.7% in the year to Jul 6, 2026

Price 50-day average 200-day averageDCF fair value ±15%Source: Yahoo Finance · chart data as of Jul 6, 2026

Key Metrics

Market Cap

$15.46B

P/E

60.99x

Forward P/E (est.)

76.03x

ROE

2.9%

Revenue Growth

2.7%

EPS Growth

-19.8%

Profit Margin

7.7%

FCF Yield

5.0%

Debt / Equity

1.31x

ROIC

—

Interest Coverage

—

Current Ratio

—

Dividend Yield

6.0%

Implied Growth (rev. DCF)

6.5%

Rating Score

23/100

Business Overview

Research

Healthpeak Properties (DOC) is a large-cap company in the Health Care REITs industry, part of the Real Estate sector of the S&P 500, with a market value around $15.46B.

In its latest reported year it generated about $2.82B in revenue and $71.35M in net profit.

Our model rates DOC Weak (23/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.

Technical Analysis (Educational)

Research

Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what DOC's chart says today, with each tool explained.

Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. DOC trades near $18.86, around its 50-day average ($19.30) and 200-day average ($17.90). Price tangled in its moving averages means there is no clear trend — the stock is ranging.

Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 64 it is in neutral territory — neither stretched nor washed out.

MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently positive — short-term momentum is improving.

Volatility — ATR. Average True Range is the typical daily move. DOC's is $0.50 (~2.7% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.

Support & resistance. In the month to Jul 6, 2026, DOC found buyers near $19.23 (support) and sellers near $21.98 (resistance); its 52-week range then was $15.70–$21.98. A decisive break beyond either edge often marks the next move.

Volume. The latest session traded 1.0× the 20-day average — about normal. Rising volume on up-days suggests real buying; on down-days, real selling.

Educational information to help you read a chart — not a recommendation or a forecast. The indicators were last computed on Jul 6, 2026; the price is current.

Revenue Growth

Research
How to read an income statement

4Y CAGR

10.5%

1/4 checks passedRevenue growingRevenue growth beats sector midpointEPS growingEPS growing faster than revenue

Revenue moved from $2.13B in 2016 to $2.82B in 2025, a 3.2% compound annual growth rate. The most recent year was roughly flat (2.7%) year over year. Slower, mature growth is common for established businesses.

Profitability

Research
What profit margins tell you
1/3 checks passedProfitableNet margin above sector midpointROE above 12%

Gross Margin

58.9%

Operating Margin

21.7%

Net Margin

2.5%

ROE

2.9%

Healthpeak Properties keeps about 7.7% of each sales dollar as net profit, with a 58.9% gross margin and 21.7% operating margin. Return on equity is 2.9%. Margins are moderate — typical of a competitive but profitable business.

Debt Analysis

Research
1/2 checks passedDebt under 1× equityDebt under 2× equity

Total Debt

$10.03B

Net Debt

$8.41B

Net Debt / EBITDA

—

Debt / Equity

1.31x

Leverage: debt-to-equity is 1.3x. That is a moderate, manageable debt load for most businesses. It carries roughly $10.03B of total debt against $1.63B of cash.

Cash Flow Analysis

Research
3/3 checks passedPositive free cash flowFCF yield above 2%Market expects achievable growth (<8%)

Operating CF

$1.25B

Free Cash Flow

$357.01M

FCF Margin

12.6%

In the latest year Healthpeak Properties produced about $1.25B of operating cash flow and $357.01M of free cash flow after capital spending. That is a free-cash-flow yield of about 5.0% on today's price. Strong cash generation funds dividends, buybacks, and reinvestment.

Dividend Safety

Can the payout survive a bad year? Scored from filed cash flow, earnings coverage, and the raise/cut record.

What to look for in a dividend stock
At RiskSafety score: 11/100

Coverage is weak, the payout was cut recently, or it's being financed rather than earned — treat the current yield as fragile.

Dividend yield

6.0%

Per share (latest FY)

$1.22

Total paid (latest FY)

$849.10M

History on record

10 years

Free-cash-flow coverage0/100

dividend uses 238% of free cash flow

Earnings payout ratio0/100

1190% of net income paid out

Raise streak38/100

total dividends increased 3 years in a row

Cut history0/100

payout was cut at least once in the last 10 years

Coverage uses the latest fiscal year as filed with the SEC; the streak counts total dollars paid (per-share figures can carry split artifacts). Educational information, not income advice.

Valuation Analysis

Research
What is a reasonable P/E ratio?
1/4 checks passedPositive earnings (P/E meaningful)P/E below sector's upper bandForward P/E below trailing (earnings growing)Trading below DCF fair value

P/E

60.99x

P/S

5.11x

P/B

1.44x

EV / EBITDA

—

DOC trades at 61.0x trailing earnings (about 76.0x on estimated forward earnings), 5.1x sales, and 1.4x book value. Reverse-engineering today's price implies the market expects roughly 6.5% long-term free-cash-flow growth. That is a rich multiple that prices in a lot of future growth.

DCF Fair Value (Educational)

A two-stage discounted cash flow on real SEC-filed free cash flow — the intrinsic-value anchor professional analysts triangulate from.

How this DCF estimate is calculated

DCF fair value / share

$8.26

Current price

$18.86

-56% · Above fair-value estimate

Starting FCF (latest 10-K)

$357.01M

Growth, years 1–5

2.7%

Fade to terminal, years 6–10

2.5%

Discount rate

9.0%

PV of 10-yr free cash flow$2.61B
PV of terminal value$3.09B
Estimated equity value$5.70B
Shares outstanding690M

Cash flows grow at the stage-1 rate (trailing revenue growth, capped at 20%) for five years, fade to 2.5% by year 10, and continue at that rate forever (Gordon terminal value), all discounted at 9.0%. Small changes in assumptions move the result a lot — treat this as one reference point, not a target price. Educational only, not investment advice.

Metrics vs. Sector Range

Where DOC sits versus the Real Estate companies we cover.

TTM P/E
61.0xExpensive
Forward P/E
76.0xExpensive
P/S ratio
5.1xFair
Revenue growth
2.7%Average
EPS growth
-19.8%Weak
Gross margin
58.9%Average
Net margin
7.7%Average
ROE
2.9%Weak

Bands show the middle half (25th–75th percentile) of the 33 Real Estate companies in our coverage that have fundamentals data — the peer-relative anchor professional comps analysis uses. Context only — not investment advice.

Sector Peer Comparison

How DOC stacks up against its Real Estate peers — valuation, profitability, and growth versus the sector median.

Among the 33 rated Real Estate companies we cover, DOC ranks #33 by our overall rating. It trades at a premium versus the sector on earnings (61x P/E vs. 29.9x median) with a lower return on equity (2.9% vs. 8.0%) and slower revenue growth (2.7% vs. 5.3%).

P/E vs sector

61x

median 29.9x

ROE vs sector

2.9%

median 8.0%

Growth vs sector

2.7%

median 5.3%

Sector rank

#33

of 33 rated

CompanyP/ERev Gr.Rating
DOCThis stock61x2.7%Weak· 23
VTR172x20.7%Neutral· 44
WELL117.4x37.5%Neutral· 48
JLL17x11.2%Favorable· 58
CPT34.2x1.3%Favorable· 59
HST16.3x6.2%Favorable· 67
REG24.6x7.8%Favorable· 71
MAA34.7x0.8%Neutral· 42
Real Estate median29.9x5.3%53/100

Valuation vs. quality map

sector medianVTRWELLJLLCPTHSTREGMAADOCP/E — cheaper ←→ pricierROE — more profitable ↑

The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.

Compare side by side

Peers are the closest Real Estate companies by sub-industry and size, preferring ones with full data. Sector medians and rank use the 33 rated companies among the 41 Real Estate stocks we cover. Educational, not a recommendation.

5-Year Projection Model

Project revenue → earnings → price. Edit the assumptions to build your own case.

What drives this projection, and its limits

2030 scenario price range (Base Case)

$4.43 – $7.30

vs. $18.86 today · implied CAGR -25% – -17%

Metric20262027202820292030
Revenue$2.91B$2.99B$3.08B$3.18B$3.27B
Net income$87.22M$89.83M$92.53M$95.30M$98.16M
EPS$0.11$0.11$0.11$0.12$0.12
Share price (low)$3.94$4.05$4.18$4.30$4.43
Share price (high)$6.49$6.68$6.88$7.09$7.30
CAGR (low–high)-79% / -66%-54% / -40%-40% / -29%-31% / -22%-25% / -17%

Educational scenario model, not a forecast or investment advice. It starts from the latest annual revenue in SEC filings. By default, growth is trailing revenue growth (held between 3% and 45% a year), the net margin is the latest one (held between 3% and 50%, so a loss-making company is modeled with a small profit), and the Base case P/E runs from 60% to 100% of today's. Carrying recent growth forward five years can miss badly in either direction. Outputs are only as good as the assumptions.

Bull Case

The case for DOC:

  • Healthy free-cash-flow yield (~5.0%) funds buybacks and dividends.
  • Pays a 6.0% dividend on top of any price gains.

Bear Case

The case against DOC:

  • Revenue growth is slow (2.7%), limiting the upside engine.
  • A rich 61.0x earnings multiple prices in a lot of growth.
  • Our model's overall read is Weak (23/100).

Key Risks

Research

Valuation risk — at 61.0x earnings, disappointing results could compress the multiple.

Balance-sheet risk — debt/equity of 1.3x magnifies the impact of higher rates or weaker earnings.

Growth risk — sluggish revenue (2.7%) leaves little margin for execution missteps.

Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.

Investment Thesis

Research

On balance, the fundamentals screen weakly: Healthpeak Properties is a large-cap real estate business growing at a mature pace, with modest profitability, and a heavier debt load to watch. It trades at 61.0x earnings, which our model scores Weak (23/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.

Analyst Ratings

What 26 Wall Street analysts covering DOC recommend (September 2026). Consensus is a useful sanity check — not a substitute for your own homework.

Hold
consensus · score 3.5 / 5 across 26 analysts
Strong Buy 4Buy 6Hold 16Sell 0Strong Sell 0

Analysts have turned more cautious over the last three months (-14 pts of buy ratings).

Latest SEC Filings

DOC's most recent filings, straight from SEC EDGAR. Annual and quarterly reports are the deep dives; 8-Ks flag material events the moment they happen. How to read a 10-K

DOC — frequently asked questions

Is DOC a good stock to buy?

We don't give buy or sell advice. Our model rates Healthpeak Properties Weak (23/100) based on its growth, profitability, financial health, and valuation — use that as a research starting point and make your own decision.

What is DOC's rating on The Stocks School?

Healthpeak Properties currently scores 23/100 (Weak) on our transparent model, which weighs real fundamentals: growth, margins, returns on capital, balance-sheet strength, and valuation.

How our ratings work →
Where does DOC's data come from?

Live price data plus real fundamentals and 5-year financials pulled directly from Healthpeak Properties's SEC filings — refreshed automatically, not hand-entered.

How is the 5-year projection for DOC calculated?

It's a scenario model. It starts from the latest annual revenue and net margin in SEC filings, grows revenue at an assumed rate (trailing revenue growth by default), and applies a P/E range built around today's multiple to show the resulting share-price range. When a stock has no growth or P/E data, the starting values are placeholders. It's a tool for thinking, not a prediction.

Is this DOC analysis financial advice?

No. Everything on this page is educational research, not financial advice or a recommendation to buy or sell DOC. Always do your own research and consider a licensed professional.

Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.

Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.